Clinical trial results:
A Phase 2b, Open Label, Multi-Center, Extension Study to Evaluate the Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis Meningococcal B Recombinant Vaccine Administered at 12, 18 or 24 Months of Age in Subjects Who Previously Received a Three-Dose Primary Series of the Novartis Meningococcal B Recombinant Vaccine as Infants in Study V72P12.

Due to a system error, the data reported in v1 is not correct and has been removed from public view.

Summary

EudraCT number	2009-011676-30
Trial protocol	GB ES DE BE IT CZ
Global end of trial date	09 January 2012

Results information

Result version number	v2 (current)
This version publication date	03 June 2016
First version publication date	08 January 2015
Version creation reason	

Trial information

Trial identification

Sponsor protocol code	V72P12E1

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00944034
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Novartis Vaccines and Diagnostics SRL
Sponsor organisation address	Via Fiorentina 1, Siena, Italy, 53100
Public contact	Posting Director, Novartis Vaccines and Diagnostics SRL, RegistryContactVaccinesUS@novartis.com
Scientific contact	Posting Director, Novartis Vaccines and Diagnostics SRL, RegistryContactVaccinesUS@novartis.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMEA-000139-PIP01-07
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No	Yes

1901/2006 apply to this trial?	

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	21 November 2012
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	09 January 2012
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To demonstrate a sufficient immune response following a fourth (booster) dose of rMenB+OMV NZ in at least one of the time points, when given at 12, 18 or 24 months of age to toddlers previously primed with three doses of rMenB+OMV NZ as infants at 2, 4 and 6 months of age (with concomitant routine vaccines).

Protection of trial subjects:

This clinical study was designated, implemented and reported in accordance with the International Conference on Harmonization (ICH) Harmonized Tripartite Guidelines for Good Clinical Practice (GCP), with applicable local regulations (including European Directive 2001/20/EC, US Code of Federal Regulations (CFR) Title 21, and Japanese Ministry of Health, Labor and Welfare), and with the ethical principles laid down in the Declaration of Helsinki.

Standard immunization practices should be observed and care should be taken to administer the injection intramuscularly. As with all injectable vaccines, appropriate medical treatment and supervision should be readily available in case of anaphylactic reactions following administration of the study vaccine, in accordance with local practice/guidelines such as epinephrine 1:1000 and diphenhydramine.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	13 July 2009
Long term follow-up planned	Yes
Long term follow-up rationale	Safety
Long term follow-up duration	6 Months
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Czech Republic: 252
Country: Number of subjects enrolled	Belgium: 183
Country: Number of subjects enrolled	Germany: 295
Country: Number of subjects enrolled	Italy: 290
Country: Number of subjects enrolled	Spain: 106
Country: Number of subjects enrolled	United Kingdom: 462
Worldwide total number of subjects	1588
EEA total number of subjects	1588

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	1588
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Subjects were enrolled from 6 centres in Belgium, 4 in Czech, 24 in Germany, 5 in Italy, 16 in Spain and 4 in UK who had previously participated in and completed the study V72P12.

Pre-assignment

Screening details:

All enrolled subjects were included in the trial.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	B+R246_12

Arm description:

Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age.

Arm type	Experimental
Investigational medicinal product name	rMenB+OMV NZ
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Each dose of 0.5 mL

Arm title	B+R246_18

Arm description:

Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age.

Arm type	Experimental
Investigational medicinal product name	rMenB+OMV NZ
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Each dose of 0.5 mL

Arm title	B+R246_24

Arm description:

Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age.

Arm type	Experimental

Investigational medicinal product name	rMenB+OMV NZ
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Each dose of 0.5 mL

Arm title	B246_12

Arm description:

Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age.

Arm type	Experimental
Investigational medicinal product name	rMenB+OMV NZ
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Each dose of 0.5 mL

Arm title	B246_18

Arm description:

Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3,5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ at 18 months of age.

Arm type	Experimental
Investigational medicinal product name	rMenB+OMV NZ
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Each dose of 0.5 mL

Arm title	B246_24

Arm description:

Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ at 24 months of age.

Arm type	Experimental
Investigational medicinal product name	rMenB+OMV NZ
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Each dose of 0.5 mL

Arm title	B+R234_12

Arm description:

Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ at 12 months of age.

Arm type	Experimental

Investigational medicinal product name	rMenB+OMV NZ
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Each dose of 0.5 mL

Arm title	B+R234_18

Arm description:

Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age.

Arm type	Experimental
Investigational medicinal product name	rMenB+OMV NZ
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Each dose of 0.5 mL

Arm title	B+R234_24

Arm description:

Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age.

Arm type	Experimental
Investigational medicinal product name	rMenB+OMV NZ
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Each dose of 0.5 mL

Arm title	B12 14

Arm description:

Previously received two catch-up doses of rMenB+OMV NZ vaccine at 12 and14 months of age.

Arm type	Experimental
Investigational medicinal product name	rMenB+OMV NZ
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Each dose of 0.5 mL

Arm title	B18 20

Arm description:

Previously received two catch-up doses of rMenB+OMV NZ vaccine at 18 and 20 months of age.

Arm type	Experimental
Investigational medicinal product name	rMenB+OMV NZ
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:
Each dose of 0.5 mL

Arm title	B24 26

Arm description:
Previously received two catch-up doses of rMenB+OMV NZ vaccine at 24 and 26 months of age..

Arm type	Experimental
Investigational medicinal product name	rMenB+OMV NZ
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:
Each dose of 0.5 mL

Number of subjects in period 1	B+R246_12	B+R246_18	B+R246_24
Started	188	157	152
Completed	183	150	143
Not completed	5	7	9
Adverse event, serious fatal	-	-	1
Consent withdrawn by subject	3	2	6
Inappropriate enrollment	-	1	-
Unable to classify	-	-	-
Lost to follow-up	-	4	2
Protocol deviation	2	-	-
Administrative reason	-	-	-

Number of subjects in period 1	B246_12	B246_18	B246_24
Started	174	164	143
Completed	170	150	123
Not completed	4	14	20
Adverse event, serious fatal	-	-	-
Consent withdrawn by subject	2	5	8
Inappropriate enrollment	1	2	1
Unable to classify	-	-	1
Lost to follow-up	-	5	7
Protocol deviation	1	2	3
Administrative reason	-	-	-

Number of subjects in period 1	B+R234_12	B+R234_18	B+R234_24
Started	106	78	73
Completed	102	73	63
Not completed	4	5	10
Adverse event, serious fatal	-	-	-
Consent withdrawn by subject	2	2	3
Inappropriate enrollment	-	-	1
Unable to classify	1	1	-
Lost to follow-up	-	1	5
Protocol deviation	-	1	1
Administrative reason	1	-	-

Number of subjects in period 1	B12 14	B18 20	B24 26
Started	246	51	56
Completed	236	50	52
Not completed	10	1	4
Adverse event, serious fatal	-	-	-
Consent withdrawn by subject	4	-	4
Inappropriate enrollment	1	-	-
Unable to classify	-	-	-
Lost to follow-up	1	1	-
Protocol deviation	4	-	-
Administrative reason	-	-	-

Baseline characteristics

Reporting groups

Reporting group title	B+R246_12
Reporting group description:	
Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age.	
Reporting group title	B+R246_18
Reporting group description:	
Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age.	
Reporting group title	B+R246_24
Reporting group description:	
Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age.	
Reporting group title	B246_12
Reporting group description:	
Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age.	
Reporting group title	B246_18
Reporting group description:	
Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3,5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ at 18 months of age.	
Reporting group title	B246_24
Reporting group description:	
Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ at 24 months of age.	
Reporting group title	B+R234_12
Reporting group description:	
Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ at 12 months of age.	
Reporting group title	B+R234_18
Reporting group description:	
Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age.	
Reporting group title	B+R234_24
Reporting group description:	
Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age.	
Reporting group title	B12 14
Reporting group description:	
Previously received two catch-up doses of rMenB+OMV NZ vaccine at 12 and14 months of age.	
Reporting group title	B18 20
Reporting group description:	
Previously received two catch-up doses of rMenB+OMV NZ vaccine at 18 and 20 months of age.	
Reporting group title	B24 26
Reporting group description:	
Previously received two catch-up doses of rMenB+OMV NZ vaccine at 24 and 26 months of age..	

Reporting group values	B+R246_12	B+R246_18	B+R246_24
Number of subjects	188	157	152
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	188	153	10
Children (2-11 years)	0	0	135
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	0	0	0
From 65-84 years	0	0	0
85 years and over	0	0	0
Not Available	0	4	7
Age continuous Units: months			
arithmetic mean	12.6	18.1	24
standard deviation	± 1.2	± 0.6	± 0.4
Gender categorical Units: Subjects			
Female	78	73	77
Male	110	84	75

Reporting group values	B246_12	B246_18	B246_24
Number of subjects	174	164	143
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	174	155	5
Children (2-11 years)	0	0	121
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	0	0	0
From 65-84 years	0	0	0
85 years and over	0	0	0
Not Available	0	9	17
Age continuous Units: months			
arithmetic mean	12.7	18.1	24
standard deviation	± 0.9	± 0.5	± 0.3
Gender categorical Units: Subjects			
Female	81	80	75
Male	93	84	68

Reporting group values	B+R234_12	B+R234_18	B+R234_24
Number of subjects	106	78	73

Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	104	75	6
Children (2-11 years)	0	0	60
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	0	0	0
From 65-84 years	0	0	0
85 years and over	0	0	0
Not Available	2	3	7
Age continuous Units: months			
arithmetic mean	12.8	18	24
standard deviation	± 1.4	± 0.4	± 0.5
Gender categorical Units: Subjects			
Female	62	41	34
Male	44	37	39

Reporting group values	B12 14	B18 20	B24 26
Number of subjects	246	51	56
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	243	51	2
Children (2-11 years)	0	0	54
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	0	0	0
From 65-84 years	0	0	0
85 years and over	0	0	0
Not Available	3	0	0
Age continuous Units: months			
arithmetic mean	12.6	18	24
standard deviation	± 1.3	± 0.2	± 0.2
Gender categorical Units: Subjects			
Female	115	23	23
Male	131	28	33

Reporting group values	Total		
Number of subjects	1588		

Age categorical Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	1166		
Children (2-11 years)	370		
Adolescents (12-17 years)	0		
Adults (18-64 years)	0		
From 65-84 years	0		
85 years and over	0		
Not Available	52		
Age continuous Units: months			
arithmetic mean			
standard deviation	-		
Gender categorical Units: Subjects			
Female	762		
Male	826		

Subject analysis sets

Subject analysis set title	Per-protocol Population
Subject analysis set type	Per protocol

Subject analysis set description:

All enrolled subjects who correctly received the vaccine, provided evaluable serum samples at the relevant time points and had no major protocol violation as defined prior to the end of the study.

Subject analysis set title	Safety Population
Subject analysis set type	Safety analysis

Subject analysis set description:

All subjects in the Exposed population who provided post vaccination and post-baseline safety data.

Reporting group values	Per-protocol Population	Safety Population	
Number of subjects	1288	1519	
Age categorical Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	1288	1519	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	0	0	
From 65-84 years	0	0	
85 years and over	0	0	
Not Available	0	0	

Age continuous Units: months			
arithmetic mean	16.9	17.1	
standard deviation	± 4.7	± 4.7	
Gender categorical Units: Subjects			
Female			
Male			

End points

End points reporting groups

Reporting group title	B+R246_12
Reporting group description:	
Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age.	
Reporting group title	B+R246_18
Reporting group description:	
Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age.	
Reporting group title	B+R246_24
Reporting group description:	
Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age.	
Reporting group title	B246_12
Reporting group description:	
Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age.	
Reporting group title	B246_18
Reporting group description:	
Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3,5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ at 18 months of age.	
Reporting group title	B246_24
Reporting group description:	
Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ at 24 months of age.	
Reporting group title	B+R234_12
Reporting group description:	
Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ at 12 months of age.	
Reporting group title	B+R234_18
Reporting group description:	
Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age.	
Reporting group title	B+R234_24
Reporting group description:	
Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age.	
Reporting group title	B12 14
Reporting group description:	
Previously received two catch-up doses of rMenB+OMV NZ vaccine at 12 and14 months of age.	
Reporting group title	B18 20
Reporting group description:	
Previously received two catch-up doses of rMenB+OMV NZ vaccine at 18 and 20 months of age.	
Reporting group title	B24 26
Reporting group description:	
Previously received two catch-up doses of rMenB+OMV NZ vaccine at 24 and 26 months of age..	
Subject analysis set title	Per-protocol Population
Subject analysis set type	Per protocol
Subject analysis set description:	
All enrolled subjects who correctly received the vaccine, provided evaluable serum samples at the relevant time points and had no major protocol violation as defined prior to the end of the study.	

Subject analysis set title	Safety Population
Subject analysis set type	Safety analysis

Subject analysis set description:

All subjects in the Exposed population who provided post vaccination and post-baseline safety data.

Primary: Percentages of Subjects With Serum Bactericidal Antibody Titers ≥1:5 After Receiving a Fourth (Booster) Dose of rMenB+OMV NZ Vaccination in subjects who previously received 3 doses of rMenB+OMV NZ and routine vaccines at 2, 4 and 6 months of age

End point title	Percentages of Subjects With Serum Bactericidal Antibody Titers ≥1:5 After Receiving a Fourth (Booster) Dose of rMenB+OMV NZ Vaccination in subjects who previously received 3 doses of rMenB+OMV NZ and routine vaccines at 2, 4 and 6 months of age[1][2]

End point description:

Immunogenicity was assessed in terms of percentage of subjects with serum bactericidal antibody (SBA) titers ≥1:5 against N.meningitidis serogroup reference strains H44/76, NZ98/254 and 5/99, one month after the fourth (booster) dose of meningococcal B vaccine at 12 or 18 or24 months of age who were previously vaccinated with 3 doses of rMenB+OMV NZ and routine vaccines at 2, 4 and 6 months of age.

End point type	Primary

End point timeframe:

1 month after booster

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: statistical analyses not applicable for this endpoint.

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: statistical analyses not applicable for this endpoint.

End point values	B+R246_12	B+R246_18	B+R246_24	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	159[3]	118	101	
Units: Percentages of subjects				
number (confidence interval 98.3%)				
hSBA≥ 1: 5 (H44/76 strain)	97 (93 to 99)	100 (96 to 100)	100 (95 to 100)	
hSBA≥ 1: 5 (5/99 strain)	100 (97 to 100)	100 (96 to 100)	100 (95 to 100)	
hSBA≥ 1: 5 (NZ 98/254 strain)	95 (89 to 98)	77 (67 to 86)	84 (74 to 92)	
hSBA≥ 1: 5 (M10713 strain)	0 (0 to 0)	0 (0 to 0)	0 (0 to 0)	

Notes:

[3] - 44/76-SL (N= 158, 116,101)
5/99 (N= 156,118,100)
NZ98/254 (N= 159,118,103)
M107713 (N= 0,0,0)

Statistical analyses

No statistical analyses for this end point

Secondary: Percentages of Subjects With SBA Titers ≥1:5 After Receiving a Fourth (Booster) Dose of rMenB+OMV NZ Vaccination in subjects who previously received 3 doses of rMenB+OMV NZ at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age.

End point title	Percentages of Subjects With SBA Titers ≥1:5 After Receiving a Fourth (Booster) Dose of rMenB+OMV NZ Vaccination in subjects who previously received 3 doses of rMenB+OMV NZ at

	2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age.[4]

End point description:

Immunogenicity was assessed in terms of percentage of subjects with serum bactericidal antibody (SBA) titers ≥1:5 against N.meningitidis serogroup reference strains H44/76, NZ98/254 and 5/99, one month after the fourth (booster) dose of meningococcal B vaccine at 12 or 18 or 24 months of age who were previously vaccinated with 3 doses of rMenB+OMV NZ at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age.

End point type	Secondary

End point timeframe:

1 month after booster

Notes:

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: statistical analyses not applicable for this endpoint.

End point values	B246_12	B246_18	B246_24	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	142[5]	111	95	
Units: Percentages of subjects				
number (confidence interval 98.3%)				
hSBA≥ 1: 5 (H44/76 strain)	100 (97 to 100)	99 (94 to 100)	100 (95 to 100)	
hSBA≥ 1: 5 (5/99 strain)	100 (97 to 100)	100 (96 to 100)	100 (95 to 100)	
hSBA≥ 1: 5 (NZ 98/254 strain)	96 (90 to 99)	86 (76 to 93)	89 (80 to 96)	
hSBA≥ 1: 5 (M10713 strain)	0 (0 to 0)	0 (0 to 0)	0 (0 to 0)	

Notes:

[5] - H44/76 (N=138,111,93)
5/99 (N=142,110,92)
NZ 98/254 (N=142,111,95)
M10713 (N=0,0,0)

Statistical analyses

No statistical analyses for this end point

Secondary: Percentages of Subjects With Serum Bactericidal Antibody Titers ≥1:5 After Receiving a Fourth (Booster) Dose of rMenB+OMV NZ Vaccination in subjects who previously received 3 doses of rMenB+OMV NZ and routine vaccines at 2, 3 and 4 months of age.

End point title	Percentages of Subjects With Serum Bactericidal Antibody Titers ≥1:5 After Receiving a Fourth (Booster) Dose of rMenB+OMV NZ Vaccination in subjects who previously received 3 doses of rMenB+OMV NZ and routine vaccines at 2, 3 and 4 months of age.[6]

End point description:

Immunogenicity was assessed in terms of percentage of subjects with serum bactericidal antibody (SBA) titers ≥1:5 against N.meningitidis serogroup reference strains H44/76, NZ98/254 and 5/99, one month after the fourth (booster) dose of meningococcal B vaccine at 12 or 18 or24 months of age who were previously vaccinated with 3 doses of rMenB+OMV NZ and routine vaccines at 2, 3 and 4 months of age.

End point type	Secondary

End point timeframe:

1 month after booster

Notes:

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: statistical analyses not applicable for this endpoint.

End point values	B+R234_12	B+R234_18	B+R234_24	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	86[7]	56	48	
Units: Percentages of subjects				
number (confidence interval 98.3%)				
hSBA≥ 1: 5 (H44/76 strain)	100 (94 to 100)	98 (88 to 100)	100 (91 to 100)	
hSBA≥ 1: 5 (5/99 strain)	100 (94 to 100)	100 (92 to 100)	100 (90 to 100)	
hSBA≥ 1: 5 (NZ 98/254 strain)	97 (89 to 100)	80 (65 to 91)	96 (83 to 100)	
hSBA≥ 1: 5 (M10713 strain)	76 (62 to 87)	74 (57 to 87)	95 (81 to 100)	

Notes:

[7] - H44/76 (N=83,56,48)
5/99 (N=84,56,46)
NZ 98/254 (N=86,56,48)
M10713 (N=67,50,41)

Statistical analyses

No statistical analyses for this end point

Secondary: Geometric Mean Titers (GMTs) in subjects one month After Receiving a Fourth (Booster) Dose of rMenB+OMV NZ Vaccination in subjects at 12 18 or 24 months of age who previously received 3 doses of rMenB+OMV NZ at 2, 3 and 4 or 2, 4 and 6 months of age.

End point title	Geometric Mean Titers (GMTs) in subjects one month After Receiving a Fourth (Booster) Dose of rMenB+OMV NZ Vaccination in subjects at 12 18 or 24 months of age who previously received 3 doses of rMenB+OMV NZ at 2, 3 and 4 or 2, 4 and 6 months of age.[8]

End point description:

The serum antibody titers one month after the fourth (booster) dose of meningococcal B vaccine at 12 or 18 or24 months of age who were previously vaccinated with 3 doses of rMenB+OMV NZ at 2, 3 and 4 or 2, 4 and 6 months of age, are reported as geometric mean titers (GMTs) against N.meningitidis serogroup reference strains H44/76, NZ98/254 and 5/99.

End point type	Secondary

End point timeframe:

1 month after booster

Notes:

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: statistical analyses not applicable for this endpoint.

End point values	B+R246_12	B+R246_18	B+R246_24	B246_12
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	159	118	103	142
Units: Titers				
geometric mean (confidence interval 95%)				
H44/76 (N=158,116,101,138,111,93,83,56,48)	125 (106 to 148)	123 (101 to 149)	108 (88 to 133)	178 (149 to 213)
5/99 (N=156,116,100,142,110,92,84,56,46)	1276 (1092 to 1491)	2183 (1824 to 2611)	1820 (1497 to 2212)	1713 (1454 to 2020)
NZ 98/254 (N=159,118,103,142,111,95,86,56,48)	36 (29 to 44)	15 (12 to 19)	17 (14 to 22)	34 (27 to 42)
M10713 (N=0,0,0,0,0,0,67,50,41)	0 (0 to 0)	0 (0 to 0)	0 (0 to 0)	0 (0 to 0)

End point values	B246_18	B246_24	B+R234_12	B+R234_18
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	111	95	86	56
Units: Titers				
geometric mean (confidence interval 95%)				
H44/76 (N=158,116,101,138,111,93,83,56,48)	164 (135 to 200)	152 (122 to 188)	135 (108 to 170)	92 (70 to 120)
5/99 (N=156,116,100,142,110,92,84,56,46)	2058 (1710 to 2476)	2739 (2233 to 3361)	1558 (1262 to 1923)	1486 (1148 to 1924)
NZ 98/254 (N=159,118,103,142,111,95,86,56,48)	17 (14 to 22)	19 (15 to 25)	47 (36 to 62)	17 (12 to 24)
M10713 (N=0,0,0,0,0,0,67,50,41)	0 (0 to 0)	0 (0 to 0)	12 (8.52 to 17)	15 (10 to 23)

End point values	B+R234_24			
Subject group type	Reporting group			
Number of subjects analysed	48			
Units: Titers				
geometric mean (confidence interval 95%)				
H44/76 (N=158,116,101,138,111,93,83,56,48)	128 (95 to 172)			
5/99 (N=156,116,100,142,110,92,84,56,46)	2081 (1564 to 2771)			
NZ 98/254 (N=159,118,103,142,111,95,86,56,48)	33 (23 to 47)			
M10713 (N=0,0,0,0,0,0,67,50,41)	26 (17 to 41)			

Statistical analyses

No statistical analyses for this end point

Secondary: GMTs in subjects one month after the fourth (booster) dose of meningococcal B vaccine at 12 months of age previously vaccinated with 3 doses of rMenB+OMV NZ at 2, 3 and 4 or 2, 4 and 6 months of age and single dose of rMenB+OMV NZ given at same age

End point title	GMTs in subjects one month after the fourth (booster) dose of meningococcal B vaccine at 12 months of age previously vaccinated with 3 doses of rMenB+OMV NZ at 2, 3 and 4 or 2, 4 and 6 months of age and single dose of rMenB+OMV NZ given at same age[9]

End point description:

Characterization of immunological memory by serum antibody titers one month after the fourth (booster) dose of meningococcal B vaccine at 12 months of age who were previously vaccinated with 3 doses of rMenB+OMV NZ at 2, 3 and 4 or 2, 4 and 6 months of age and single dose of rMenB+OMV NZ given at same ages, are reported as geometric mean titers (GMTs) against N.meningitidis serogroup reference strains H44/76, NZ98/254 and 5/99.

End point type	Secondary

End point timeframe:

1 month after booster

Notes:

[9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: statistical analyses not applicable for this endpoint.

End point values	B+R246_12	B246_12	B+R234_12	B12 14
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	159[10]	142	86	221
Units: Titers				
geometric mean (confidence interval 98.3%)				
H44/76 strain	125 (102 to 154)	179 (144 to 223)	137 (104 to 181)	18 (15 to 21)
5/99 strain	1301 (1076 to 1573)	1763 (1441 to 2157)	1607 (1243 to 2077)	49 (42 to 58)
NZ 98/254 strain	37 (29 to 46)	35 (27 to 44)	48 (36 to 65)	3.71 (3.06 to 4.5)

Notes:

[10] - H44/76 (N=158,138,83,217)
5/99 (N=156,142,84,216)
NZ98/254 (N=159,142,86,221)

Statistical analyses

No statistical analyses for this end point

Secondary: GMTs one month after the fourth (booster) dose of meningococcal B vaccine at 18 and 24months of age who were previously vaccinated with 3 doses of rMenB+OMV NZ at 2, 3 and 4 or 2, 4 and 6 months of age and single dose of rMenB+OMV NZ given at same ages

End point title	GMTs one month after the fourth (booster) dose of meningococcal B vaccine at 18 and 24months of age who were previously vaccinated with 3 doses of rMenB+OMV NZ at 2, 3 and 4 or 2, 4 and 6 months of age and single dose of rMenB+OMV NZ given at same ages[11]

End point description:

Characterization of immunological memory by serum antibody titers one month after the fourth (booster) dose of meningococcal B vaccine at 18 and 24months of age who were previously vaccinated with 3 doses of rMenB+OMV NZ at 2, 3 and 4 or 2, 4 and 6 months of age and single dose of rMenB+OMV NZ given at same ages, are reported as geometric mean titers (GMTs) against N.meningitidis serogroup reference strains H44/76, NZ98/254 and 5/99.

End point type	Secondary

End point timeframe:

1 month after booster

Notes:

[11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: statistical analyses not applicable for this endpoint.

End point values	B+R246_18	B+R246_24	B246_18	B246_24
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	118	111	113	95
Units: Titers				
geometric mean (confidence interval 95%)				
H44/76 (N= 116,101,111,93,56,48,46,52)	126 (104 to 154)	110 (89 to 136)	162 (132 to 198)	155 (124 to 193)
5/99 (N=118,100,110,92,56,46,48,50)	2195 (1790 to 2691)	1811 (1449 to 2262)	2034 (1648 to 2511)	2735 (2166 to 3455)
NZ 98/254 (N=118,103,111,95,56,48,50,55)	16 (12 to 20)	18 (14 to 23)	17 (14 to 22)	20 (15 to 26)

End point values	B+R234_18	B+R234_24	B18 20	B24 26
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	56	48	50	55
Units: Titers				
geometric mean (confidence interval 95%)				
H44/76 (N= 116,101,111,93,56,48,46,52)	93 (70 to 123)	132 (97 to 180)	18 (13 to 25)	14 (10 to 19)
5/99 (N=118,100,110,92,56,46,48,50)	1483 (1107 to 1986)	2087 (1508 to 2889)	41 (30 to 56)	30 (22 to 41)
NZ 98/254 (N=118,103,111,95,56,48,50,55)	17 (12 to 25)	34 (23 to 49)	2.76 (1.87 to 4.08)	2.1 (1.44 to 3.07)

Statistical analyses

No statistical analyses for this end point

Secondary: Two-dose catch-up regimen of rMenB+OMV NZ in unprimed toddlers aged 12, 18 or 24 months

End point title	Two-dose catch-up regimen of rMenB+OMV NZ in unprimed toddlers aged 12, 18 or 24 months[12]

End point description:

Immunogenicity evaluation of a two-dose catch-up regimen of rMenB+OMV NZ in unprimed toddlers aged 12, 18 or 24 months as measured by serum antibody titers one month after the second vaccination f meningococcal B vaccine at 18 and 24months of age who were previously vaccinated with 3 doses of rMenB+OMV NZ reported as geometric mean titers (GMTs) against N.meningitidis serogroup reference strains H44/76, NZ98/254 and 5/99.

End point type	Secondary

End point timeframe:

1 month after second vaccination

Notes:

[12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: statistical analyses not applicable for this endpoint.

End point values	B12 14	B18 20	B24 26	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	207	47	53	
Units: Titers				
geometric mean (confidence interval 95%)				
H44/76 strain	188 (164 to 216)	171 (130 to 224)	177 (136 to 231)	
5/99 strain	635 (548 to 735)	491 (359 to 672)	559 (417 to 749)	
NZ 98/254 strain	40 (35 to 47)	23 (17 to 30)	24 (18 to 32)	
M10713 strain	0 (0 to 0)	14 (8.02 to 23)	18 (11 to 29)	

Statistical analyses

No statistical analyses for this end point

Secondary: Geometric Mean Concentrations against vaccine antigen 287-953 one month after fourth booster dose to previously primed toddlers at 12, 18 or 24 months of age.

End point title	Geometric Mean Concentrations against vaccine antigen 287-953 one month after fourth booster dose to previously primed toddlers at 12, 18 or 24 months of age.[13]

End point description:

Immunogenicity evaluation against vaccine antigen 287-953 one month after fourth booster dose to previously primed toddlers at 12, 18 or 24 months measured by ELISA.

End point type	Secondary

End point timeframe:

1 month after booster vaccination

Notes:

[13] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: statistical analyses not applicable for this endpoint.

End point values	B+R246_12	B+R246_18	B+R246_24	B246_12
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	162	119	108	145
Units: IU/mL				
geometric mean (confidence interval 95%)				
MENB-ELISA287-953	5334 (4670 to 6093)	6395 (5474 to 7470)	6864 (5826 to 8087)	6605 (5733 to 7609)

End point values	B246_18	B246_24	B+R234_12	B+R234_18
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	114	98	86	58
Units: IU/mL				
geometric mean (confidence interval				

95%)				
MENB-ELISA287-953	6418 (5477 to 7520)	8120 (6833 to 9649)	6125 (5110 to 7342)	5952 (4771 to 7426)

End point values	B+R234_24			
Subject group type	Reporting group			
Number of subjects analysed	48			
Units: IU/mL				
geometric mean (confidence interval 95%)				
MENB-ELISA287-953	6774 (5305 to 8649)			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of children reporting solicited local and systemic adverse events after receiving a fourth booster dose of rMenB+OMV NZ vaccine at 12, 18 or 24 months of age.

End point title	Number of children reporting solicited local and systemic adverse events after receiving a fourth booster dose of rMenB+OMV NZ vaccine at 12, 18 or 24 months of age.[14]

End point description:

The safety and tolerability of the 4th booster dose rMenB+OMV NZ vaccine in children (12, 18 or 24 months age) is reported as number of subjects with solicited local and systemic adverse events.

End point type	Secondary

End point timeframe:

From day 1 to day 7 after vaccination

Notes:

[14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: statistical analyses not applicable for this endpoint.

End point values	B246_12	B246_18	B246_24	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	170	153	126	
Units: Number				
Any	156	135	116	
Any Local	137	119	113	
Injection site Tenderness(N=170,152,125)	104	104	105	
Injection site Erythema	117	94	94	
Injection site Induration	93	62	73	
Injection site Swelling	57	52	50	
Any Systemic	134	118	101	
ChangeEat.Habits	66	59	51	
Sleepiness	63	56	52	

Vomiting	8	9	8	
Diarrhea	37	23	27	
Irritbility	104	91	83	
Unusual Crying	52	51	40	
Rash	7	3	7	
Fever (>= 38C)	52	55	28	
Any Other	59	59	40	
Body Temp. >38 C	118	98	98	
Medical Attend. Fever	5	5	2	
Antipypr. Med.Used	32	28	25	
Antipytr. Med.Used	37	39	21	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of children reporting solicited local and systemic adverse events after receiving a two-dose catch-up regimen of rMenB+OMV NZ vaccine at 12, 18 or 24 months of age.

End point title	Number of children reporting solicited local and systemic adverse events after receiving a two-dose catch-up regimen of rMenB+OMV NZ vaccine at 12, 18 or 24 months of age.[15]

End point description:

The safety and tolerability of the two-dose catch-up regimen of rMenB+OMV NZ vaccine in children (12, 18 or 24 months age) is reported as number of subjects with solicited local and systemic adverse events.

End point type	Secondary

End point timeframe:

From day 1 to day 7 after vaccination

Notes:

[15] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: statistical analyses not applicable for this endpoint.

End point values	B12 14	B18 20	B24 26	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	239	51	54	
Units: Number				
Injection site Tenderness (vaccination 1)	151	35	47	
Injection site Tenderness (vaccination 2)	143	32	42	
Injection site Erythema (vaccination 1)	151	32	39	
Injection site Erythema (vaccination 2)	148	33	31	
Injection site Induration (vaccination 1)	112	20	27	
Injection site Induration (vaccination 2)	101	24	22	
Injection site Swelling (vaccination 1)	81	15	19	
Injection site Swelling (vaccination 2)	72	18	19	
Change in Eating habits (vaccination 1)	95	13	25	
Change in Eating habits (vaccination 2)	83	19	21	
Sleepiness (vaccination 1)	106	21	18	

Sleepiness (vaccination 2)	78	16	18	
Vomiting (vaccination 1)	19	5	6	
Vomiting (vaccination 2)	18	1	4	
Diarrhea (vaccination 1)	43	13	20	
Diarrhea (vaccination 2)	35	5	7	
Irritbility (vaccination 1)	156	23	28	
Irritbilit (vaccination 2)	126	27	23	
Unusual Crying (vaccination 1)	81	13	15	
Unusual Crying (vaccination 2)	67	14	15	
Rash (vaccination 1)	13	5	2	
Rash (vaccination 2)	10	4	0	
Fever (>= 38C) (vaccination 1)	83	14	15	
Fever (>= 38C) (vaccination 2)	74	15	13	
Body Temp.<38 C (vaccination 1)	156	37	39	
Body Temp.<38 C (vaccination 2)	163	36	39	
Medical Attend. Fever (vaccination 1)	9	2	1	
Medical Attend. Fever (vaccination 2)	5	1	0	
Antipypr. Med.Used (vaccination 1)	49	8	8	
Antipypr. Med.Used (vaccination 2)	45	9	11	
Antipytr. Med.Used (vaccination 1)	66	9	11	
Antipytr. Med.Used (vaccination 2)	54	11	7	

Statistical analyses

No statistical analyses for this end point

Secondary: Geometric Mean Concentrations against vaccine antigen 287-953 one month after booster given after a two-dose catch-up regimen in toddlers starting at 12, 18 or 24 months of age.

End point title	Geometric Mean Concentrations against vaccine antigen 287-953 one month after booster given after a two-dose catch-up regimen in toddlers starting at 12, 18 or 24 months of age.[16]

End point description:

Immunogenicity evaluation against vaccine antigen 287-953 one month after booster given after a two-dose catch-up regimen in toddlers starting at 12, 18 or 24 months of age.one month after fourth booster dose to previously primed toddlers at 12, 18 or 24 months of age measured by ELISA

End point type	Secondary

End point timeframe:

1 month after booster vaccination

Notes:

[16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: statistical analyses not applicable for this endpoint.

End point values	B12 14	B18 20	B24 26	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	177	44	47	
Units: IU/mL				
geometric mean (confidence interval 95%)	122 (101 to 147)	121 (84 to 176)	100 (69 to 144)	

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From day 1 to day 7 after vaccination

Assessment type	Non-systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	17.1

Reporting groups

Reporting group title	B+R246_18

Reporting group description:

Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age.

Reporting group title	B+R246_12

Reporting group description:

Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age.

Reporting group title	B246_18

Reporting group description:

Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3,5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ at 18 months of age.

Reporting group title	B+R246_24

Reporting group description:

Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age.

Reporting group title	B246_12

Reporting group description:

Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age.

Reporting group title	B246_24

Reporting group description:

Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3,5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ at 24 months of age.

Reporting group title	B+R234_12

Reporting group description:

Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ at 12 months of age.

Reporting group title	B+R234_18

Reporting group description:

Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age.

Reporting group title	B+R234_24

Reporting group description:

Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age.

Reporting group title	B12 14

Reporting group description:

Previously received two catch-up doses of rMenB+OMV NZ vaccine at 12 and14 months of age.

Reporting group title	B18 20

Reporting group description:

Previously received two catch-up doses of rMenB+OMV NZ vaccine at 18 and 20 months of age.

Reporting group title	B24 26

Reporting group description:

Previously received two catch-up doses of rMenB+OMV NZ vaccine at 24 and 26 months of age.

Serious adverse events	B+R246_18	B+R246_12	B246_18
Total subjects affected by serious adverse events			
subjects affected / exposed	3 / 152 (1.97%)	5 / 185 (2.70%)	7 / 153 (4.58%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Injury, poisoning and procedural complications			
Concussion			
subjects affected / exposed	0 / 152 (0.00%)	0 / 185 (0.00%)	1 / 153 (0.65%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laceration			
subjects affected / exposed	0 / 152 (0.00%)	0 / 185 (0.00%)	0 / 153 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Head injury			
subjects affected / exposed	0 / 152 (0.00%)	0 / 185 (0.00%)	0 / 153 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skull fracture			
subjects affected / exposed	0 / 152 (0.00%)	0 / 185 (0.00%)	0 / 153 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Accidental exposure to product			
subjects affected / exposed	0 / 152 (0.00%)	0 / 185 (0.00%)	0 / 153 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Congenital aural fistula			

subjects affected / exposed	0 / 152 (0.00%)	0 / 185 (0.00%)	0 / 153 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Convulsion			
subjects affected / exposed	0 / 152 (0.00%)	0 / 185 (0.00%)	0 / 153 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epilepsy			
subjects affected / exposed	0 / 152 (0.00%)	0 / 185 (0.00%)	1 / 153 (0.65%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile convulsion			
subjects affected / exposed	0 / 152 (0.00%)	0 / 185 (0.00%)	0 / 153 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Autism			
subjects affected / exposed	0 / 152 (0.00%)	0 / 185 (0.00%)	0 / 153 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Petit mal Epilepsy			
subjects affected / exposed	0 / 152 (0.00%)	0 / 185 (0.00%)	0 / 153 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	0 / 152 (0.00%)	0 / 185 (0.00%)	0 / 153 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Social circumstances			
Walking disability			
subjects affected / exposed	0 / 152 (0.00%)	0 / 185 (0.00%)	0 / 153 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Gastrointestinal disorders			
Coeliac Disease			
subjects affected / exposed	1 / 152 (0.66%)	0 / 185 (0.00%)	0 / 153 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acetonaemic vomiting			
subjects affected / exposed	0 / 152 (0.00%)	0 / 185 (0.00%)	0 / 153 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysphagia			
subjects affected / exposed	0 / 152 (0.00%)	0 / 185 (0.00%)	0 / 153 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stomatitis			
subjects affected / exposed	0 / 152 (0.00%)	0 / 185 (0.00%)	0 / 153 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	0 / 152 (0.00%)	0 / 185 (0.00%)	1 / 153 (0.65%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wheezing			
subjects affected / exposed	0 / 152 (0.00%)	0 / 185 (0.00%)	0 / 153 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia aspiration			
subjects affected / exposed	0 / 152 (0.00%)	0 / 185 (0.00%)	0 / 153 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adenoidal hypertrophy			
subjects affected / exposed	0 / 152 (0.00%)	0 / 185 (0.00%)	0 / 153 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Skin and subcutaneous tissue disorders			
Rash			
subjects affected / exposed	0 / 152 (0.00%)	0 / 185 (0.00%)	0 / 153 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urticaria			
subjects affected / exposed	0 / 152 (0.00%)	0 / 185 (0.00%)	0 / 153 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthritis reactive			
subjects affected / exposed	0 / 152 (0.00%)	0 / 185 (0.00%)	0 / 153 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Abscess			
subjects affected / exposed	0 / 152 (0.00%)	0 / 185 (0.00%)	1 / 153 (0.65%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchiolitis			
subjects affected / exposed	0 / 152 (0.00%)	0 / 185 (0.00%)	0 / 153 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
subjects affected / exposed	0 / 152 (0.00%)	0 / 185 (0.00%)	0 / 153 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchopneumonia			
subjects affected / exposed	0 / 152 (0.00%)	1 / 185 (0.54%)	0 / 153 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear Infection			

subjects affected / exposed	0 / 152 (0.00%)	1 / 185 (0.54%)	0 / 153 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia urinary tract infection			
subjects affected / exposed	0 / 152 (0.00%)	0 / 185 (0.00%)	1 / 153 (0.65%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	1 / 152 (0.66%)	0 / 185 (0.00%)	2 / 153 (1.31%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis Rotavirus			
subjects affected / exposed	1 / 152 (0.66%)	1 / 185 (0.54%)	0 / 153 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngitis			
subjects affected / exposed	0 / 152 (0.00%)	0 / 185 (0.00%)	1 / 153 (0.65%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pharyngitis			
subjects affected / exposed	0 / 152 (0.00%)	0 / 185 (0.00%)	0 / 153 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 152 (0.00%)	2 / 185 (1.08%)	0 / 153 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus bronchiolitis			
subjects affected / exposed	0 / 152 (0.00%)	1 / 185 (0.54%)	0 / 153 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tonsillitis			

subjects affected / exposed	0 / 152 (0.00%)	1 / 185 (0.54%)	0 / 153 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eczema herpeticum			
subjects affected / exposed	0 / 152 (0.00%)	0 / 185 (0.00%)	0 / 153 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 152 (0.00%)	0 / 185 (0.00%)	0 / 153 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Periorbital cellulitis			
subjects affected / exposed	0 / 152 (0.00%)	0 / 185 (0.00%)	0 / 153 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia respiratory syncytial viral			
subjects affected / exposed	0 / 152 (0.00%)	0 / 185 (0.00%)	0 / 153 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Superinfection bacterial			
subjects affected / exposed	0 / 152 (0.00%)	0 / 185 (0.00%)	0 / 153 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	0 / 152 (0.00%)	0 / 185 (0.00%)	1 / 153 (0.65%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection			
subjects affected / exposed	0 / 152 (0.00%)	0 / 185 (0.00%)	0 / 153 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			

subjects affected / exposed	1 / 152 (0.66%)	0 / 185 (0.00%)	0 / 153 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	B+R246_24	B246_12	B246_24
Total subjects affected by serious adverse events			
subjects affected / exposed	6 / 144 (4.17%)	6 / 170 (3.53%)	1 / 126 (0.79%)
number of deaths (all causes)	1	0	0
number of deaths resulting from adverse events	0		
Injury, poisoning and procedural complications			
Concussion			
subjects affected / exposed	0 / 144 (0.00%)	1 / 170 (0.59%)	0 / 126 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laceration			
subjects affected / exposed	1 / 144 (0.69%)	0 / 170 (0.00%)	0 / 126 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Head injury			
subjects affected / exposed	0 / 144 (0.00%)	0 / 170 (0.00%)	0 / 126 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skull fracture			
subjects affected / exposed	0 / 144 (0.00%)	0 / 170 (0.00%)	0 / 126 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Accidental exposure to product			
subjects affected / exposed	0 / 144 (0.00%)	0 / 170 (0.00%)	0 / 126 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Congenital aural fistula			

subjects affected / exposed	0 / 144 (0.00%)	0 / 170 (0.00%)	0 / 126 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Convulsion			
subjects affected / exposed	1 / 144 (0.69%)	0 / 170 (0.00%)	0 / 126 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epilepsy			
subjects affected / exposed	0 / 144 (0.00%)	0 / 170 (0.00%)	0 / 126 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile convulsion			
subjects affected / exposed	2 / 144 (1.39%)	0 / 170 (0.00%)	0 / 126 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Autism			
subjects affected / exposed	0 / 144 (0.00%)	0 / 170 (0.00%)	0 / 126 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Petit mal Epilepsy			
subjects affected / exposed	0 / 144 (0.00%)	0 / 170 (0.00%)	0 / 126 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	0 / 144 (0.00%)	0 / 170 (0.00%)	0 / 126 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Social circumstances			
Walking disability			
subjects affected / exposed	0 / 144 (0.00%)	0 / 170 (0.00%)	0 / 126 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Gastrointestinal disorders			
Coeliac Disease			
subjects affected / exposed	0 / 144 (0.00%)	0 / 170 (0.00%)	0 / 126 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acetonaemic vomiting			
subjects affected / exposed	0 / 144 (0.00%)	0 / 170 (0.00%)	0 / 126 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysphagia			
subjects affected / exposed	0 / 144 (0.00%)	0 / 170 (0.00%)	0 / 126 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stomatitis			
subjects affected / exposed	0 / 144 (0.00%)	0 / 170 (0.00%)	0 / 126 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	1 / 144 (0.69%)	0 / 170 (0.00%)	0 / 126 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wheezing			
subjects affected / exposed	0 / 144 (0.00%)	1 / 170 (0.59%)	0 / 126 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia aspiration			
subjects affected / exposed	0 / 144 (0.00%)	0 / 170 (0.00%)	0 / 126 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adenoidal hypertrophy			
subjects affected / exposed	0 / 144 (0.00%)	0 / 170 (0.00%)	0 / 126 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Skin and subcutaneous tissue disorders			
Rash			
subjects affected / exposed	0 / 144 (0.00%)	1 / 170 (0.59%)	0 / 126 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urticaria			
subjects affected / exposed	0 / 144 (0.00%)	0 / 170 (0.00%)	0 / 126 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthritis reactive			
subjects affected / exposed	0 / 144 (0.00%)	1 / 170 (0.59%)	0 / 126 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Abscess			
subjects affected / exposed	0 / 144 (0.00%)	0 / 170 (0.00%)	0 / 126 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchiolitis			
subjects affected / exposed	0 / 144 (0.00%)	0 / 170 (0.00%)	1 / 126 (0.79%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
subjects affected / exposed	0 / 144 (0.00%)	1 / 170 (0.59%)	0 / 126 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchopneumonia			
subjects affected / exposed	0 / 144 (0.00%)	0 / 170 (0.00%)	0 / 126 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear Infection			

subjects affected / exposed	0 / 144 (0.00%)	0 / 170 (0.00%)	0 / 126 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia urinary tract infection			
subjects affected / exposed	0 / 144 (0.00%)	0 / 170 (0.00%)	0 / 126 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 144 (0.00%)	0 / 170 (0.00%)	0 / 126 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis Rotavirus			
subjects affected / exposed	0 / 144 (0.00%)	0 / 170 (0.00%)	0 / 126 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngitis			
subjects affected / exposed	0 / 144 (0.00%)	0 / 170 (0.00%)	0 / 126 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pharyngitis			
subjects affected / exposed	0 / 144 (0.00%)	1 / 170 (0.59%)	0 / 126 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	1 / 144 (0.69%)	0 / 170 (0.00%)	0 / 126 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus bronchiolitis			
subjects affected / exposed	0 / 144 (0.00%)	0 / 170 (0.00%)	0 / 126 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tonsillitis			

subjects affected / exposed	0 / 144 (0.00%)	0 / 170 (0.00%)	0 / 126 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eczema herpeticum			
subjects affected / exposed	0 / 144 (0.00%)	0 / 170 (0.00%)	0 / 126 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 144 (0.00%)	0 / 170 (0.00%)	0 / 126 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Periorbital cellulitis			
subjects affected / exposed	0 / 144 (0.00%)	0 / 170 (0.00%)	0 / 126 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia respiratory syncytial viral			
subjects affected / exposed	0 / 144 (0.00%)	0 / 170 (0.00%)	0 / 126 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Superinfection bacterial			
subjects affected / exposed	0 / 144 (0.00%)	0 / 170 (0.00%)	0 / 126 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	0 / 144 (0.00%)	0 / 170 (0.00%)	0 / 126 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection			
subjects affected / exposed	0 / 144 (0.00%)	1 / 170 (0.59%)	0 / 126 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			

subjects affected / exposed	0 / 144 (0.00%)	1 / 170 (0.59%)	0 / 126 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	B+R234_12	B+R234_18	B+R234_24
Total subjects affected by serious adverse events			
subjects affected / exposed	5 / 104 (4.81%)	5 / 74 (6.76%)	3 / 66 (4.55%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Injury, poisoning and procedural complications			
Concussion			
subjects affected / exposed	0 / 104 (0.00%)	0 / 74 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laceration			
subjects affected / exposed	0 / 104 (0.00%)	0 / 74 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Head injury			
subjects affected / exposed	0 / 104 (0.00%)	0 / 74 (0.00%)	1 / 66 (1.52%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skull fracture			
subjects affected / exposed	0 / 104 (0.00%)	0 / 74 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Accidental exposure to product			
subjects affected / exposed	0 / 104 (0.00%)	1 / 74 (1.35%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Congenital aural fistula			

subjects affected / exposed	0 / 104 (0.00%)	0 / 74 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Convulsion			
subjects affected / exposed	0 / 104 (0.00%)	0 / 74 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epilepsy			
subjects affected / exposed	0 / 104 (0.00%)	0 / 74 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile convulsion			
subjects affected / exposed	1 / 104 (0.96%)	0 / 74 (0.00%)	1 / 66 (1.52%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Autism			
subjects affected / exposed	0 / 104 (0.00%)	0 / 74 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Petit mal Epilepsy			
subjects affected / exposed	1 / 104 (0.96%)	0 / 74 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	1 / 104 (0.96%)	0 / 74 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Social circumstances			
Walking disability			
subjects affected / exposed	0 / 104 (0.00%)	0 / 74 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Gastrointestinal disorders			
Coeliac Disease			
subjects affected / exposed	0 / 104 (0.00%)	0 / 74 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acetonaemic vomiting			
subjects affected / exposed	0 / 104 (0.00%)	0 / 74 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysphagia			
subjects affected / exposed	0 / 104 (0.00%)	0 / 74 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stomatitis			
subjects affected / exposed	0 / 104 (0.00%)	1 / 74 (1.35%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	0 / 104 (0.00%)	0 / 74 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wheezing			
subjects affected / exposed	0 / 104 (0.00%)	0 / 74 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia aspiration			
subjects affected / exposed	0 / 104 (0.00%)	0 / 74 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adenoidal hypertrophy			
subjects affected / exposed	0 / 104 (0.00%)	0 / 74 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Skin and subcutaneous tissue disorders			
Rash			
subjects affected / exposed	0 / 104 (0.00%)	0 / 74 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urticaria			
subjects affected / exposed	0 / 104 (0.00%)	1 / 74 (1.35%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthritis reactive			
subjects affected / exposed	0 / 104 (0.00%)	0 / 74 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Abscess			
subjects affected / exposed	0 / 104 (0.00%)	0 / 74 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchiolitis			
subjects affected / exposed	0 / 104 (0.00%)	0 / 74 (0.00%)	1 / 66 (1.52%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
subjects affected / exposed	0 / 104 (0.00%)	0 / 74 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchopneumonia			
subjects affected / exposed	0 / 104 (0.00%)	0 / 74 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear Infection			

subjects affected / exposed	0 / 104 (0.00%)	0 / 74 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia urinary tract infection			
subjects affected / exposed	0 / 104 (0.00%)	0 / 74 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 104 (0.00%)	2 / 74 (2.70%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis Rotavirus			
subjects affected / exposed	0 / 104 (0.00%)	0 / 74 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngitis			
subjects affected / exposed	0 / 104 (0.00%)	0 / 74 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pharyngitis			
subjects affected / exposed	0 / 104 (0.00%)	0 / 74 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	1 / 104 (0.96%)	0 / 74 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus bronchiolitis			
subjects affected / exposed	0 / 104 (0.00%)	0 / 74 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tonsillitis			

subjects affected / exposed	0 / 104 (0.00%)	0 / 74 (0.00%)	1 / 66 (1.52%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eczema herpeticum			
subjects affected / exposed	1 / 104 (0.96%)	0 / 74 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 104 (0.00%)	0 / 74 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Periorbital cellulitis			
subjects affected / exposed	0 / 104 (0.00%)	0 / 74 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia respiratory syncytial viral			
subjects affected / exposed	0 / 104 (0.00%)	0 / 74 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Superinfection bacterial			
subjects affected / exposed	0 / 104 (0.00%)	0 / 74 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	0 / 104 (0.00%)	0 / 74 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection			
subjects affected / exposed	0 / 104 (0.00%)	0 / 74 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			

subjects affected / exposed	0 / 104 (0.00%)	0 / 74 (0.00%)	0 / 66 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	B12 14	B18 20	B24 26
Total subjects affected by serious adverse events			
subjects affected / exposed	16 / 239 (6.69%)	0 / 51 (0.00%)	1 / 55 (1.82%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Injury, poisoning and procedural complications			
Concussion			
subjects affected / exposed	1 / 239 (0.42%)	0 / 51 (0.00%)	1 / 55 (1.82%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laceration			
subjects affected / exposed	0 / 239 (0.00%)	0 / 51 (0.00%)	0 / 55 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Head injury			
subjects affected / exposed	1 / 239 (0.42%)	0 / 51 (0.00%)	0 / 55 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skull fracture			
subjects affected / exposed	1 / 239 (0.42%)	0 / 51 (0.00%)	0 / 55 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Accidental exposure to product			
subjects affected / exposed	0 / 239 (0.00%)	0 / 51 (0.00%)	0 / 55 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Congenital aural fistula			

subjects affected / exposed	1 / 239 (0.42%)	0 / 51 (0.00%)	0 / 55 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Convulsion			
subjects affected / exposed	0 / 239 (0.00%)	0 / 51 (0.00%)	0 / 55 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epilepsy			
subjects affected / exposed	0 / 239 (0.00%)	0 / 51 (0.00%)	0 / 55 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile convulsion			
subjects affected / exposed	3 / 239 (1.26%)	0 / 51 (0.00%)	0 / 55 (0.00%)
occurrences causally related to treatment / all	1 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Autism			
subjects affected / exposed	1 / 239 (0.42%)	0 / 51 (0.00%)	0 / 55 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Petit mal Epilepsy			
subjects affected / exposed	0 / 239 (0.00%)	0 / 51 (0.00%)	0 / 55 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	0 / 239 (0.00%)	0 / 51 (0.00%)	0 / 55 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Social circumstances			
Walking disability			
subjects affected / exposed	1 / 239 (0.42%)	0 / 51 (0.00%)	0 / 55 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Gastrointestinal disorders			
Coeliac Disease			
subjects affected / exposed	0 / 239 (0.00%)	0 / 51 (0.00%)	0 / 55 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acetonaemic vomiting			
subjects affected / exposed	1 / 239 (0.42%)	0 / 51 (0.00%)	0 / 55 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysphagia			
subjects affected / exposed	1 / 239 (0.42%)	0 / 51 (0.00%)	0 / 55 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stomatitis			
subjects affected / exposed	0 / 239 (0.00%)	0 / 51 (0.00%)	0 / 55 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	0 / 239 (0.00%)	0 / 51 (0.00%)	0 / 55 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wheezing			
subjects affected / exposed	1 / 239 (0.42%)	0 / 51 (0.00%)	0 / 55 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia aspiration			
subjects affected / exposed	1 / 239 (0.42%)	0 / 51 (0.00%)	0 / 55 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adenoidal hypertrophy			
subjects affected / exposed	1 / 239 (0.42%)	0 / 51 (0.00%)	0 / 55 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Skin and subcutaneous tissue disorders			
Rash			
subjects affected / exposed	0 / 239 (0.00%)	0 / 51 (0.00%)	0 / 55 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urticaria			
subjects affected / exposed	0 / 239 (0.00%)	0 / 51 (0.00%)	0 / 55 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthritis reactive			
subjects affected / exposed	0 / 239 (0.00%)	0 / 51 (0.00%)	0 / 55 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Abscess			
subjects affected / exposed	0 / 239 (0.00%)	0 / 51 (0.00%)	0 / 55 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchiolitis			
subjects affected / exposed	0 / 239 (0.00%)	0 / 51 (0.00%)	0 / 55 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
subjects affected / exposed	1 / 239 (0.42%)	0 / 51 (0.00%)	0 / 55 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchopneumonia			
subjects affected / exposed	1 / 239 (0.42%)	0 / 51 (0.00%)	0 / 55 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear Infection			

subjects affected / exposed	0 / 239 (0.00%)	0 / 51 (0.00%)	0 / 55 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia urinary tract infection			
subjects affected / exposed	0 / 239 (0.00%)	0 / 51 (0.00%)	0 / 55 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	2 / 239 (0.84%)	0 / 51 (0.00%)	0 / 55 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis Rotavirus			
subjects affected / exposed	0 / 239 (0.00%)	0 / 51 (0.00%)	0 / 55 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngitis			
subjects affected / exposed	0 / 239 (0.00%)	0 / 51 (0.00%)	0 / 55 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pharyngitis			
subjects affected / exposed	0 / 239 (0.00%)	0 / 51 (0.00%)	0 / 55 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 239 (0.00%)	0 / 51 (0.00%)	0 / 55 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory syncytial virus bronchiolitis			
subjects affected / exposed	0 / 239 (0.00%)	0 / 51 (0.00%)	0 / 55 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tonsillitis			

subjects affected / exposed	0 / 239 (0.00%)	0 / 51 (0.00%)	0 / 55 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eczema herpeticum			
subjects affected / exposed	0 / 239 (0.00%)	0 / 51 (0.00%)	0 / 55 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	1 / 239 (0.42%)	0 / 51 (0.00%)	0 / 55 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Periorbital cellulitis			
subjects affected / exposed	1 / 239 (0.42%)	0 / 51 (0.00%)	0 / 55 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia respiratory syncytial viral			
subjects affected / exposed	1 / 239 (0.42%)	0 / 51 (0.00%)	0 / 55 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Superinfection bacterial			
subjects affected / exposed	1 / 239 (0.42%)	0 / 51 (0.00%)	0 / 55 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	0 / 239 (0.00%)	0 / 51 (0.00%)	0 / 55 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection			
subjects affected / exposed	0 / 239 (0.00%)	0 / 51 (0.00%)	0 / 55 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			

subjects affected / exposed	0 / 239 (0.00%)	0 / 51 (0.00%)	0 / 55 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	B+R246_18	B+R246_12	B246_18
Total subjects affected by non-serious adverse events			
subjects affected / exposed	147 / 152 (96.71%)	180 / 185 (97.30%)	139 / 153 (90.85%)
Nervous system disorders			
Somnolence			
subjects affected / exposed	61 / 152 (40.13%)	72 / 185 (38.92%)	56 / 153 (36.60%)
occurrences (all)	67	77	66
General disorders and administration site conditions			
Crying			
subjects affected / exposed	43 / 152 (28.29%)	56 / 185 (30.27%)	51 / 153 (33.33%)
occurrences (all)	48	61	56
Induration			
subjects affected / exposed	0 / 152 (0.00%)	2 / 185 (1.08%)	3 / 153 (1.96%)
occurrences (all)	0	2	3
Injection site erythema			
subjects affected / exposed	100 / 152 (65.79%)	127 / 185 (68.65%)	94 / 153 (61.44%)
occurrences (all)	104	134	103
Injection site induration			
subjects affected / exposed	74 / 152 (48.68%)	101 / 185 (54.59%)	62 / 153 (40.52%)
occurrences (all)	86	122	77
Injection site pain			
subjects affected / exposed	114 / 152 (75.00%)	107 / 185 (57.84%)	104 / 153 (67.97%)
occurrences (all)	119	110	110
Injection site swelling			
subjects affected / exposed	53 / 152 (34.87%)	73 / 185 (39.46%)	52 / 153 (33.99%)
occurrences (all)	56	79	58
Pyrexia			
subjects affected / exposed	57 / 152 (37.50%)	78 / 185 (42.16%)	59 / 153 (38.56%)
occurrences (all)	63	99	78
Swelling			

subjects affected / exposed	1 / 152 (0.66%)	1 / 185 (0.54%)	2 / 153 (1.31%)
occurrences (all)	1	1	2
Gastrointestinal disorders			
Constipation			
subjects affected / exposed	2 / 152 (1.32%)	2 / 185 (1.08%)	1 / 153 (0.65%)
occurrences (all)	2	2	1
Diarrhoea			
subjects affected / exposed	26 / 152 (17.11%)	39 / 185 (21.08%)	27 / 153 (17.65%)
occurrences (all)	30	51	30
Enteritis			
subjects affected / exposed	0 / 152 (0.00%)	5 / 185 (2.70%)	3 / 153 (1.96%)
occurrences (all)	0	5	3
Teething			
subjects affected / exposed	3 / 152 (1.97%)	8 / 185 (4.32%)	0 / 153 (0.00%)
occurrences (all)	3	8	0
Vomiting			
subjects affected / exposed	16 / 152 (10.53%)	15 / 185 (8.11%)	12 / 153 (7.84%)
occurrences (all)	19	19	13
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	12 / 152 (7.89%)	14 / 185 (7.57%)	8 / 153 (5.23%)
occurrences (all)	16	16	10
Skin and subcutaneous tissue disorders			
Dermatitis diaper			
subjects affected / exposed	2 / 152 (1.32%)	9 / 185 (4.86%)	5 / 153 (3.27%)
occurrences (all)	2	10	6
Erythema			
subjects affected / exposed	2 / 152 (1.32%)	0 / 185 (0.00%)	2 / 153 (1.31%)
occurrences (all)	2	0	2
Rash			
subjects affected / exposed	9 / 152 (5.92%)	9 / 185 (4.86%)	5 / 153 (3.27%)
occurrences (all)	12	10	5
Dermatitis			
subjects affected / exposed	1 / 152 (0.66%)	4 / 185 (2.16%)	0 / 153 (0.00%)
occurrences (all)	1	4	0
Psychiatric disorders			

Eating disorder			
subjects affected / exposed	70 / 152 (46.05%)	64 / 185 (34.59%)	59 / 153 (38.56%)
occurrences (all)	82	68	66
Irritability			
subjects affected / exposed	100 / 152 (65.79%)	110 / 185 (59.46%)	91 / 153 (59.48%)
occurrences (all)	118	119	105
Infections and infestations			
Bronchitis			
subjects affected / exposed	11 / 152 (7.24%)	7 / 185 (3.78%)	7 / 153 (4.58%)
occurrences (all)	15	8	12
Candida nappy rash			
subjects affected / exposed	0 / 152 (0.00%)	0 / 185 (0.00%)	0 / 153 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis			
subjects affected / exposed	11 / 152 (7.24%)	11 / 185 (5.95%)	10 / 153 (6.54%)
occurrences (all)	12	12	12
Ear infection			
subjects affected / exposed	8 / 152 (5.26%)	12 / 185 (6.49%)	5 / 153 (3.27%)
occurrences (all)	9	20	5
Fungal infection			
subjects affected / exposed	0 / 152 (0.00%)	2 / 185 (1.08%)	0 / 153 (0.00%)
occurrences (all)	0	2	0
Gastroenteritis			
subjects affected / exposed	6 / 152 (3.95%)	17 / 185 (9.19%)	5 / 153 (3.27%)
occurrences (all)	7	19	6
Infection			
subjects affected / exposed	0 / 152 (0.00%)	1 / 185 (0.54%)	3 / 153 (1.96%)
occurrences (all)	0	1	4
Influenza			
subjects affected / exposed	4 / 152 (2.63%)	3 / 185 (1.62%)	2 / 153 (1.31%)
occurrences (all)	4	3	2
Lice infestation			
subjects affected / exposed	0 / 152 (0.00%)	0 / 185 (0.00%)	0 / 153 (0.00%)
occurrences (all)	0	0	0
Nasopharyngitis			

subjects affected / exposed	6 / 152 (3.95%)	14 / 185 (7.57%)	12 / 153 (7.84%)
occurrences (all)	6	20	15
Otitis media			
subjects affected / exposed	4 / 152 (2.63%)	3 / 185 (1.62%)	4 / 153 (2.61%)
occurrences (all)	6	3	4
Pharyngitis			
subjects affected / exposed	8 / 152 (5.26%)	7 / 185 (3.78%)	14 / 153 (9.15%)
occurrences (all)	10	8	18
Respiratory tract infection			
subjects affected / exposed	3 / 152 (1.97%)	9 / 185 (4.86%)	3 / 153 (1.96%)
occurrences (all)	3	15	4
Rhinitis			
subjects affected / exposed	5 / 152 (3.29%)	10 / 185 (5.41%)	4 / 153 (2.61%)
occurrences (all)	5	11	5
Scarlet fever			
subjects affected / exposed	1 / 152 (0.66%)	0 / 185 (0.00%)	2 / 153 (1.31%)
occurrences (all)	1	0	2
Tonsillitis			
subjects affected / exposed	9 / 152 (5.92%)	6 / 185 (3.24%)	6 / 153 (3.92%)
occurrences (all)	9	6	7
Upper respiratory tract infection			
subjects affected / exposed	8 / 152 (5.26%)	10 / 185 (5.41%)	15 / 153 (9.80%)
occurrences (all)	10	12	19
Varicella			
subjects affected / exposed	1 / 152 (0.66%)	4 / 185 (2.16%)	2 / 153 (1.31%)
occurrences (all)	1	4	2
Viral infection			
subjects affected / exposed	6 / 152 (3.95%)	12 / 185 (6.49%)	10 / 153 (6.54%)
occurrences (all)	7	12	11

Non-serious adverse events	B+R246_24	B246_12	B246_24
Total subjects affected by non-serious adverse events			
subjects affected / exposed	140 / 144 (97.22%)	163 / 170 (95.88%)	116 / 126 (92.06%)
Nervous system disorders			
Somnolence			

subjects affected / exposed	72 / 144 (50.00%)	63 / 170 (37.06%)	52 / 126 (41.27%)
occurrences (all)	77	74	55
General disorders and administration site conditions			
Crying			
subjects affected / exposed	46 / 144 (31.94%)	52 / 170 (30.59%)	40 / 126 (31.75%)
occurrences (all)	49	60	45
Induration			
subjects affected / exposed	2 / 144 (1.39%)	3 / 170 (1.76%)	4 / 126 (3.17%)
occurrences (all)	2	3	4
Injection site erythema			
subjects affected / exposed	109 / 144 (75.69%)	117 / 170 (68.82%)	94 / 126 (74.60%)
occurrences (all)	112	128	97
Injection site induration			
subjects affected / exposed	76 / 144 (52.78%)	93 / 170 (54.71%)	73 / 126 (57.94%)
occurrences (all)	84	114	84
Injection site pain			
subjects affected / exposed	118 / 144 (81.94%)	104 / 170 (61.18%)	105 / 126 (83.33%)
occurrences (all)	120	106	108
Injection site swelling			
subjects affected / exposed	63 / 144 (43.75%)	57 / 170 (33.53%)	50 / 126 (39.68%)
occurrences (all)	65	61	51
Pyrexia			
subjects affected / exposed	50 / 144 (34.72%)	60 / 170 (35.29%)	32 / 126 (25.40%)
occurrences (all)	58	78	39
Swelling			
subjects affected / exposed	2 / 144 (1.39%)	1 / 170 (0.59%)	2 / 126 (1.59%)
occurrences (all)	2	1	2
Gastrointestinal disorders			
Constipation			
subjects affected / exposed	1 / 144 (0.69%)	2 / 170 (1.18%)	1 / 126 (0.79%)
occurrences (all)	1	2	1
Diarrhoea			
subjects affected / exposed	32 / 144 (22.22%)	40 / 170 (23.53%)	27 / 126 (21.43%)
occurrences (all)	38	47	36
Enteritis			

subjects affected / exposed	1 / 144 (0.69%)	2 / 170 (1.18%)	3 / 126 (2.38%)
occurrences (all)	1	2	4
Teething			
subjects affected / exposed	1 / 144 (0.69%)	2 / 170 (1.18%)	0 / 126 (0.00%)
occurrences (all)	1	2	0
Vomiting			
subjects affected / exposed	11 / 144 (7.64%)	13 / 170 (7.65%)	10 / 126 (7.94%)
occurrences (all)	12	16	11
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	5 / 144 (3.47%)	13 / 170 (7.65%)	7 / 126 (5.56%)
occurrences (all)	5	17	7
Skin and subcutaneous tissue disorders			
Dermatitis diaper			
subjects affected / exposed	2 / 144 (1.39%)	6 / 170 (3.53%)	0 / 126 (0.00%)
occurrences (all)	2	6	0
Erythema			
subjects affected / exposed	1 / 144 (0.69%)	1 / 170 (0.59%)	2 / 126 (1.59%)
occurrences (all)	1	1	2
Rash			
subjects affected / exposed	20 / 144 (13.89%)	8 / 170 (4.71%)	9 / 126 (7.14%)
occurrences (all)	23	10	10
Dermatitis			
subjects affected / exposed	1 / 144 (0.69%)	4 / 170 (2.35%)	1 / 126 (0.79%)
occurrences (all)	1	4	1
Psychiatric disorders			
Eating disorder			
subjects affected / exposed	68 / 144 (47.22%)	66 / 170 (38.82%)	51 / 126 (40.48%)
occurrences (all)	73	80	57
Irritability			
subjects affected / exposed	92 / 144 (63.89%)	104 / 170 (61.18%)	83 / 126 (65.87%)
occurrences (all)	102	116	95
Infections and infestations			
Bronchitis			
subjects affected / exposed	5 / 144 (3.47%)	19 / 170 (11.18%)	5 / 126 (3.97%)
occurrences (all)	6	22	5

Candida nappy rash			
subjects affected / exposed	0 / 144 (0.00%)	0 / 170 (0.00%)	1 / 126 (0.79%)
occurrences (all)	0	0	1
Conjunctivitis			
subjects affected / exposed	3 / 144 (2.08%)	10 / 170 (5.88%)	7 / 126 (5.56%)
occurrences (all)	3	12	7
Ear infection			
subjects affected / exposed	6 / 144 (4.17%)	13 / 170 (7.65%)	6 / 126 (4.76%)
occurrences (all)	6	14	7
Fungal infection			
subjects affected / exposed	0 / 144 (0.00%)	1 / 170 (0.59%)	0 / 126 (0.00%)
occurrences (all)	0	2	0
Gastroenteritis			
subjects affected / exposed	4 / 144 (2.78%)	9 / 170 (5.29%)	7 / 126 (5.56%)
occurrences (all)	4	10	7
Infection			
subjects affected / exposed	2 / 144 (1.39%)	0 / 170 (0.00%)	2 / 126 (1.59%)
occurrences (all)	2	0	7
Influenza			
subjects affected / exposed	1 / 144 (0.69%)	3 / 170 (1.76%)	1 / 126 (0.79%)
occurrences (all)	1	4	1
Lice infestation			
subjects affected / exposed	0 / 144 (0.00%)	1 / 170 (0.59%)	0 / 126 (0.00%)
occurrences (all)	0	1	0
Nasopharyngitis			
subjects affected / exposed	10 / 144 (6.94%)	13 / 170 (7.65%)	4 / 126 (3.17%)
occurrences (all)	12	16	4
Otitis media			
subjects affected / exposed	2 / 144 (1.39%)	6 / 170 (3.53%)	2 / 126 (1.59%)
occurrences (all)	2	6	3
Pharyngitis			
subjects affected / exposed	3 / 144 (2.08%)	5 / 170 (2.94%)	6 / 126 (4.76%)
occurrences (all)	5	8	7
Respiratory tract infection			
subjects affected / exposed	2 / 144 (1.39%)	6 / 170 (3.53%)	3 / 126 (2.38%)
occurrences (all)	7	6	3

Rhinitis			
subjects affected / exposed	4 / 144 (2.78%)	12 / 170 (7.06%)	7 / 126 (5.56%)
occurrences (all)	4	15	7
Scarlet fever			
subjects affected / exposed	2 / 144 (1.39%)	0 / 170 (0.00%)	1 / 126 (0.79%)
occurrences (all)	2	0	1
Tonsillitis			
subjects affected / exposed	7 / 144 (4.86%)	9 / 170 (5.29%)	3 / 126 (2.38%)
occurrences (all)	10	9	3
Upper respiratory tract infection			
subjects affected / exposed	0 / 144 (0.00%)	6 / 170 (3.53%)	5 / 126 (3.97%)
occurrences (all)	0	6	6
Varicella			
subjects affected / exposed	2 / 144 (1.39%)	2 / 170 (1.18%)	7 / 126 (5.56%)
occurrences (all)	2	2	7
Viral infection			
subjects affected / exposed	6 / 144 (4.17%)	7 / 170 (4.12%)	5 / 126 (3.97%)
occurrences (all)	6	9	5

Non-serious adverse events	B+R234_12	B+R234_18	B+R234_24
Total subjects affected by non-serious adverse events			
subjects affected / exposed	102 / 104 (98.08%)	73 / 74 (98.65%)	62 / 66 (93.94%)
Nervous system disorders			
Somnolence			
subjects affected / exposed	50 / 104 (48.08%)	33 / 74 (44.59%)	27 / 66 (40.91%)
occurrences (all)	55	33	29
General disorders and administration site conditions			
Crying			
subjects affected / exposed	41 / 104 (39.42%)	18 / 74 (24.32%)	22 / 66 (33.33%)
occurrences (all)	41	19	24
Induration			
subjects affected / exposed	2 / 104 (1.92%)	0 / 74 (0.00%)	0 / 66 (0.00%)
occurrences (all)	2	0	0
Injection site erythema			
subjects affected / exposed	76 / 104 (73.08%)	52 / 74 (70.27%)	49 / 66 (74.24%)
occurrences (all)	81	53	52
Injection site induration			

subjects affected / exposed	52 / 104 (50.00%)	41 / 74 (55.41%)	35 / 66 (53.03%)
occurrences (all)	66	46	39
Injection site pain			
subjects affected / exposed	70 / 104 (67.31%)	56 / 74 (75.68%)	51 / 66 (77.27%)
occurrences (all)	74	58	53
Injection site swelling			
subjects affected / exposed	32 / 104 (30.77%)	36 / 74 (48.65%)	25 / 66 (37.88%)
occurrences (all)	36	36	27
Pyrexia			
subjects affected / exposed	53 / 104 (50.96%)	28 / 74 (37.84%)	27 / 66 (40.91%)
occurrences (all)	66	34	28
Swelling			
subjects affected / exposed	0 / 104 (0.00%)	0 / 74 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Constipation			
subjects affected / exposed	1 / 104 (0.96%)	0 / 74 (0.00%)	0 / 66 (0.00%)
occurrences (all)	2	0	0
Diarrhoea			
subjects affected / exposed	21 / 104 (20.19%)	18 / 74 (24.32%)	13 / 66 (19.70%)
occurrences (all)	29	20	14
Enteritis			
subjects affected / exposed	2 / 104 (1.92%)	1 / 74 (1.35%)	2 / 66 (3.03%)
occurrences (all)	2	1	2
Teething			
subjects affected / exposed	3 / 104 (2.88%)	2 / 74 (2.70%)	0 / 66 (0.00%)
occurrences (all)	3	2	0
Vomiting			
subjects affected / exposed	15 / 104 (14.42%)	8 / 74 (10.81%)	2 / 66 (3.03%)
occurrences (all)	17	10	2
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	3 / 104 (2.88%)	4 / 74 (5.41%)	2 / 66 (3.03%)
occurrences (all)	3	7	2
Skin and subcutaneous tissue disorders			

Dermatitis diaper			
subjects affected / exposed	2 / 104 (1.92%)	4 / 74 (5.41%)	0 / 66 (0.00%)
occurrences (all)	2	5	0
Erythema			
subjects affected / exposed	1 / 104 (0.96%)	0 / 74 (0.00%)	1 / 66 (1.52%)
occurrences (all)	1	0	1
Rash			
subjects affected / exposed	10 / 104 (9.62%)	7 / 74 (9.46%)	5 / 66 (7.58%)
occurrences (all)	12	9	5
Dermatitis			
subjects affected / exposed	1 / 104 (0.96%)	1 / 74 (1.35%)	1 / 66 (1.52%)
occurrences (all)	1	1	1
Psychiatric disorders			
Eating disorder			
subjects affected / exposed	41 / 104 (39.42%)	29 / 74 (39.19%)	28 / 66 (42.42%)
occurrences (all)	48	31	29
Irritability			
subjects affected / exposed	72 / 104 (69.23%)	53 / 74 (71.62%)	44 / 66 (66.67%)
occurrences (all)	78	56	49
Infections and infestations			
Bronchitis			
subjects affected / exposed	9 / 104 (8.65%)	6 / 74 (8.11%)	4 / 66 (6.06%)
occurrences (all)	10	10	4
Candida nappy rash			
subjects affected / exposed	1 / 104 (0.96%)	1 / 74 (1.35%)	0 / 66 (0.00%)
occurrences (all)	1	1	0
Conjunctivitis			
subjects affected / exposed	5 / 104 (4.81%)	1 / 74 (1.35%)	3 / 66 (4.55%)
occurrences (all)	6	1	3
Ear infection			
subjects affected / exposed	14 / 104 (13.46%)	5 / 74 (6.76%)	3 / 66 (4.55%)
occurrences (all)	17	7	4
Fungal infection			
subjects affected / exposed	1 / 104 (0.96%)	0 / 74 (0.00%)	0 / 66 (0.00%)
occurrences (all)	1	0	0
Gastroenteritis			

subjects affected / exposed	4 / 104 (3.85%)	2 / 74 (2.70%)	0 / 66 (0.00%)
occurrences (all)	4	2	0
Infection			
subjects affected / exposed	2 / 104 (1.92%)	1 / 74 (1.35%)	1 / 66 (1.52%)
occurrences (all)	2	1	1
Influenza			
subjects affected / exposed	0 / 104 (0.00%)	2 / 74 (2.70%)	0 / 66 (0.00%)
occurrences (all)	0	2	0
Lice infestation			
subjects affected / exposed	0 / 104 (0.00%)	0 / 74 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0	0
Nasopharyngitis			
subjects affected / exposed	7 / 104 (6.73%)	5 / 74 (6.76%)	2 / 66 (3.03%)
occurrences (all)	7	6	2
Otitis media			
subjects affected / exposed	3 / 104 (2.88%)	2 / 74 (2.70%)	4 / 66 (6.06%)
occurrences (all)	3	2	4
Pharyngitis			
subjects affected / exposed	5 / 104 (4.81%)	3 / 74 (4.05%)	3 / 66 (4.55%)
occurrences (all)	5	3	3
Respiratory tract infection			
subjects affected / exposed	5 / 104 (4.81%)	2 / 74 (2.70%)	2 / 66 (3.03%)
occurrences (all)	9	2	2
Rhinitis			
subjects affected / exposed	4 / 104 (3.85%)	3 / 74 (4.05%)	1 / 66 (1.52%)
occurrences (all)	4	4	1
Scarlet fever			
subjects affected / exposed	0 / 104 (0.00%)	0 / 74 (0.00%)	0 / 66 (0.00%)
occurrences (all)	0	0	0
Tonsillitis			
subjects affected / exposed	5 / 104 (4.81%)	3 / 74 (4.05%)	3 / 66 (4.55%)
occurrences (all)	6	4	4
Upper respiratory tract infection			
subjects affected / exposed	10 / 104 (9.62%)	2 / 74 (2.70%)	0 / 66 (0.00%)
occurrences (all)	15	2	0
Varicella			

subjects affected / exposed	2 / 104 (1.92%)	0 / 74 (0.00%)	5 / 66 (7.58%)
occurrences (all)	2	0	5
Viral infection			
subjects affected / exposed	5 / 104 (4.81%)	5 / 74 (6.76%)	6 / 66 (9.09%)
occurrences (all)	6	6	6

Non-serious adverse events	B12 14	B18 20	B24 26
Total subjects affected by non-serious adverse events			
subjects affected / exposed	230 / 239 (96.23%)	50 / 51 (98.04%)	54 / 55 (98.18%)
Nervous system disorders			
Somnolence			
subjects affected / exposed	129 / 239 (53.97%)	25 / 51 (49.02%)	28 / 55 (50.91%)
occurrences (all)	206	39	44
General disorders and administration site conditions			
Crying			
subjects affected / exposed	105 / 239 (43.93%)	17 / 51 (33.33%)	25 / 55 (45.45%)
occurrences (all)	164	28	32
Induration			
subjects affected / exposed	2 / 239 (0.84%)	1 / 51 (1.96%)	4 / 55 (7.27%)
occurrences (all)	2	2	6
Injection site erythema			
subjects affected / exposed	179 / 239 (74.90%)	38 / 51 (74.51%)	41 / 55 (74.55%)
occurrences (all)	325	72	76
Injection site induration			
subjects affected / exposed	148 / 239 (61.92%)	27 / 51 (52.94%)	33 / 55 (60.00%)
occurrences (all)	251	54	55
Injection site pain			
subjects affected / exposed	187 / 239 (78.24%)	41 / 51 (80.39%)	51 / 55 (92.73%)
occurrences (all)	306	74	90
Injection site swelling			
subjects affected / exposed	107 / 239 (44.77%)	21 / 51 (41.18%)	24 / 55 (43.64%)
occurrences (all)	169	34	42
Pyrexia			
subjects affected / exposed	133 / 239 (55.65%)	24 / 51 (47.06%)	22 / 55 (40.00%)
occurrences (all)	226	41	32
Swelling			

subjects affected / exposed	1 / 239 (0.42%)	1 / 51 (1.96%)	3 / 55 (5.45%)
occurrences (all)	1	1	3
Gastrointestinal disorders			
Constipation			
subjects affected / exposed	2 / 239 (0.84%)	3 / 51 (5.88%)	2 / 55 (3.64%)
occurrences (all)	2	3	2
Diarrhoea			
subjects affected / exposed	72 / 239 (30.13%)	16 / 51 (31.37%)	21 / 55 (38.18%)
occurrences (all)	109	24	30
Enteritis			
subjects affected / exposed	4 / 239 (1.67%)	3 / 51 (5.88%)	1 / 55 (1.82%)
occurrences (all)	6	3	1
Teething			
subjects affected / exposed	15 / 239 (6.28%)	1 / 51 (1.96%)	0 / 55 (0.00%)
occurrences (all)	22	1	0
Vomiting			
subjects affected / exposed	41 / 239 (17.15%)	7 / 51 (13.73%)	8 / 55 (14.55%)
occurrences (all)	54	7	10
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	24 / 239 (10.04%)	6 / 51 (11.76%)	8 / 55 (14.55%)
occurrences (all)	27	6	11
Skin and subcutaneous tissue disorders			
Dermatitis diaper			
subjects affected / exposed	13 / 239 (5.44%)	1 / 51 (1.96%)	2 / 55 (3.64%)
occurrences (all)	16	1	2
Erythema			
subjects affected / exposed	3 / 239 (1.26%)	1 / 51 (1.96%)	3 / 55 (5.45%)
occurrences (all)	3	2	3
Rash			
subjects affected / exposed	26 / 239 (10.88%)	8 / 51 (15.69%)	4 / 55 (7.27%)
occurrences (all)	32	9	4
Dermatitis			
subjects affected / exposed	3 / 239 (1.26%)	2 / 51 (3.92%)	3 / 55 (5.45%)
occurrences (all)	4	3	3
Psychiatric disorders			

Eating disorder			
subjects affected / exposed	126 / 239 (52.72%)	21 / 51 (41.18%)	34 / 55 (61.82%)
occurrences (all)	205	39	51
Irritability			
subjects affected / exposed	177 / 239 (74.06%)	32 / 51 (62.75%)	35 / 55 (63.64%)
occurrences (all)	333	55	59
Infections and infestations			
Bronchitis			
subjects affected / exposed	19 / 239 (7.95%)	3 / 51 (5.88%)	9 / 55 (16.36%)
occurrences (all)	25	3	15
Candida nappy rash			
subjects affected / exposed	2 / 239 (0.84%)	3 / 51 (5.88%)	1 / 55 (1.82%)
occurrences (all)	2	5	1
Conjunctivitis			
subjects affected / exposed	15 / 239 (6.28%)	4 / 51 (7.84%)	4 / 55 (7.27%)
occurrences (all)	19	6	4
Ear infection			
subjects affected / exposed	29 / 239 (12.13%)	6 / 51 (11.76%)	4 / 55 (7.27%)
occurrences (all)	45	7	5
Fungal infection			
subjects affected / exposed	1 / 239 (0.42%)	1 / 51 (1.96%)	3 / 55 (5.45%)
occurrences (all)	1	1	3
Gastroenteritis			
subjects affected / exposed	10 / 239 (4.18%)	4 / 51 (7.84%)	2 / 55 (3.64%)
occurrences (all)	10	6	2
Infection			
subjects affected / exposed	2 / 239 (0.84%)	3 / 51 (5.88%)	3 / 55 (5.45%)
occurrences (all)	6	12	6
Influenza			
subjects affected / exposed	1 / 239 (0.42%)	1 / 51 (1.96%)	5 / 55 (9.09%)
occurrences (all)	1	2	7
Lice infestation			
subjects affected / exposed	0 / 239 (0.00%)	0 / 51 (0.00%)	4 / 55 (7.27%)
occurrences (all)	0	0	4
Nasopharyngitis			

subjects affected / exposed	21 / 239 (8.79%)	8 / 51 (15.69%)	7 / 55 (12.73%)
occurrences (all)	30	9	9
Otitis media			
subjects affected / exposed	11 / 239 (4.60%)	2 / 51 (3.92%)	4 / 55 (7.27%)
occurrences (all)	14	2	5
Pharyngitis			
subjects affected / exposed	16 / 239 (6.69%)	3 / 51 (5.88%)	1 / 55 (1.82%)
occurrences (all)	21	5	1
Respiratory tract infection			
subjects affected / exposed	8 / 239 (3.35%)	5 / 51 (9.80%)	6 / 55 (10.91%)
occurrences (all)	13	7	9
Rhinitis			
subjects affected / exposed	17 / 239 (7.11%)	2 / 51 (3.92%)	5 / 55 (9.09%)
occurrences (all)	22	3	5
Scarlet fever			
subjects affected / exposed	1 / 239 (0.42%)	3 / 51 (5.88%)	0 / 55 (0.00%)
occurrences (all)	1	4	0
Tonsillitis			
subjects affected / exposed	14 / 239 (5.86%)	2 / 51 (3.92%)	3 / 55 (5.45%)
occurrences (all)	14	2	5
Upper respiratory tract infection			
subjects affected / exposed	18 / 239 (7.53%)	2 / 51 (3.92%)	5 / 55 (9.09%)
occurrences (all)	24	2	5
Varicella			
subjects affected / exposed	9 / 239 (3.77%)	5 / 51 (9.80%)	1 / 55 (1.82%)
occurrences (all)	9	5	1
Viral infection			
subjects affected / exposed	21 / 239 (8.79%)	8 / 51 (15.69%)	3 / 55 (5.45%)
occurrences (all)	27	10	3

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported